Literature DB >> 11496883

Neomycin should not be used to treat hepatic encephalopathy.

W H Curioso, K E Monkemuller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11496883      PMCID: PMC1120846     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

Review 1.  ABC of diseases of liver, pancreas, and biliary system: portal hypertension-2. Ascites, encephalopathy, and other conditions.

Authors:  J E Krige; I J Beckingham
Journal:  BMJ       Date:  2001-02-17

2.  Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

Authors:  F Miglio; D Valpiani; S R Rossellini; A Ferrieri
Journal:  Curr Med Res Opin       Date:  1997       Impact factor: 2.580

3.  Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.

Authors:  R Williams; O F James; T W Warnes; M Y Morgan
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-02       Impact factor: 2.566

4.  [Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial].

Authors:  P Blanc; J P Daurès; J Liautard; R Buttigieg; D Desprez; G Pageaux; J L Allaz; G Parelon; D Larrey; H Michel
Journal:  Gastroenterol Clin Biol       Date:  1994

5.  Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.

Authors:  E Strauss; R Tramote; E P Silva; W R Caly; N Z Honain; R A Maffei; M F de Sá
Journal:  Hepatogastroenterology       Date:  1992-12
  5 in total
  1 in total

1.  Managing complications in cirrhotic patients.

Authors:  Markus Peck-Radosavljevic; Paolo Angeli; Juan Cordoba; Oliver Farges; Dominique Valla
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.